HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline.

HanchorBio Secures Japanese Patent for Engineered SIRPα-IgG4 Fusion Protein HCB101 Patent Approval Strengthens Global Intellectual Property Position and Supports International Licensing Strategy   HanchorBio today announced that the Japan Patent Office (JPO) had granted Japanese Patent No. 7795041 covering engineered SIRPα variants and their therapeutic use, providing intellectual property protection for HCB101, the company’s differentiated […]

HanchorBio Reports High Objective Response Rate with HCB101 Combination in   Second-Line Gastric Cancer Following ASCO-GI 2026 Poster Presentation Mid-dose cohorts demonstrate ~80% ORR when HCB101 is layered on the standard ramucirumab and paclitaxel in second-line gastric cancer. HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today […]

Novel fusion protein shows potent macrophage activation, T-cell restoration, and tumor microenvironment remodeling in preclinical solid tumor models.   [Taipei, Shanghai, and San Francisco | November 5, 2025] –HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the preclinical data on HCB301, a novel […]